Aptus Capital Advisors LLC Invests $344,000 in ResMed Inc. (NYSE:RMD)

Aptus Capital Advisors LLC purchased a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 1,503 shares of the medical equipment provider's stock, valued at approximately $344,000.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in ResMed by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider's stock valued at $4,156,089,000 after purchasing an additional 160,590 shares during the period. Geode Capital Management LLC grew its position in shares of ResMed by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock worth $899,860,000 after buying an additional 85,270 shares during the last quarter. Invesco Ltd. increased its stake in shares of ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock valued at $531,706,000 after buying an additional 566,046 shares during the period. Northern Trust Corp raised its holdings in shares of ResMed by 20.6% during the fourth quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider's stock valued at $389,365,000 after acquiring an additional 290,664 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in ResMed by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock worth $218,861,000 after acquiring an additional 32,973 shares during the period. Institutional investors own 54.98% of the company's stock.

Wall Street Analyst Weigh In

RMD has been the subject of several research reports. Royal Bank of Canada upped their price objective on shares of ResMed from $247.00 to $255.00 and gave the stock a "sector perform" rating in a report on Thursday, April 24th. Citigroup raised shares of ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Morgan Stanley started coverage on ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 target price on the stock. Stifel Nicolaus decreased their target price on ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of ResMed in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ResMed has a consensus rating of "Moderate Buy" and an average price target of $258.83.

Insider Activity

In related news, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20. Following the completion of the sale, the insider now owns 9,725 shares of the company's stock, valued at $2,289,265. The trade was a 48.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total transaction of $455,420.00. Following the completion of the transaction, the director now owns 75,218 shares in the company, valued at $17,127,890.78. This trade represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,949 shares of company stock valued at $11,335,320 in the last 90 days. 0.71% of the stock is currently owned by insiders.

ResMed Stock Up 0.8 %

Shares of NYSE:RMD traded up $2.03 during trading on Friday, reaching $245.12. 693,838 shares of the stock traded hands, compared to its average volume of 1,006,634. ResMed Inc. has a 52-week low of $179.42 and a 52-week high of $263.05. The stock has a market cap of $35.94 billion, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 1.53 and a beta of 0.78. The stock has a 50-day moving average of $223.37 and a two-hundred day moving average of $234.07. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The business had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the company earned $2.13 EPS. The company's quarterly revenue was up 7.9% compared to the same quarter last year. As a group, sell-side analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's payout ratio is presently 23.79%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.